OncoMatch/Multiple Myeloma (MM)/TP53 / 17p deletion
Multiple Myeloma (MM)TP53 / 17p deletion Clinical Trials
TP53 mutation and/or 17p13.1 deletion (del17p) occur in approximately 10% of newly diagnosed myeloma and up to 30–40% of relapsed/refractory cases, defining a high-risk feature per IMWG and ISS criteria. Del17p/TP53-altered myeloma has poor outcomes with standard therapy and represents an unmet need. Trials investigate novel combinations including anti-CD38 quadruplets, p53-pathway targeting agents, and CAR-T/bispecific antibody strategies specifically in high-risk cytogenetic myeloma.
Top recruiting TP53 / 17p deletion Multiple Myeloma (MM) trials
Ranked by phase and US site count.
See all trials matched to your profile →Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma
Emory University
Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma
H. Lee Moffitt Cancer Center and Research Institute
Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma
M.D. Anderson Cancer Center
Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma
Xia Zhongjun
DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China